Education
About Us
Working with TipRanks
Follow Us
Viking Therapeutics (VKTX)
NASDAQ:VKTX
VKTX Stock Chart & Stats
$31.42
$0.22(0.67%)
At close: 4:00 PM EST
$31.42
$0.22(0.67%)
Day’s Range― - ―
52-Week Range$18.92 - $81.73
Previous CloseN/A
Volume7.75M
Average Volume (3M)5.16M
Market Cap
$3.80B
Enterprise ValueN/A
Total Cash (Recent Filing)$33.88M
Total Debt (Recent Filing)$878.00K
Price to Earnings (P/E)―
Beta1.80
Next Earnings
Feb 11, 2026EPS Estimate
-0.88Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.81
Shares Outstanding112,444,960
10 Day Avg. Volume4,872,656
30 Day Avg. Volume5,158,383
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap0.00
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit0.00
Enterprise Value/Ebitda0.00
Forecast
1Y Price Target
$90.53Price Target Upside188.13% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering17
Bulls Say, Bears Say
Bulls Say
Clinical TrialsRapid enrollment rate in the Phase III VANQUISH-1 trial reflects a high degree of patient and physician enthusiasm for the program.
Competitive PositioningViking distinguishes itself with an advanced, class-leading portfolio, and its competitive positioning is seen as a key driver of both standalone and strategic value.
Financial OpportunitiesViking is well positioned as a potential M&A candidate.
Bears Say
CompetitionThe dominance of Eli Lilly and Novo Nordisk fuels debate around competition, execution, and investor psychology.
Market PressureVKTX shares are under pressure following the data release and investor call, partly due to elevated expectations and concerns around the safety/tolerability profile of oral '2735.
Viking Therapeutics News
VKTX FAQ
What was Viking Therapeutics’s price range in the past 12 months?
Viking Therapeutics lowest stock price was $18.92 and its highest was $81.73 in the past 12 months.
What is Viking Therapeutics’s market cap?
Viking Therapeutics’s market cap is $3.80B.
When is Viking Therapeutics’s upcoming earnings report date?
Viking Therapeutics’s upcoming earnings report date is Feb 11, 2026 which is in 111 days.
How were Viking Therapeutics’s earnings last quarter?
Viking Therapeutics released its earnings results on Oct 22, 2025. The company reported -$0.81 earnings per share for the quarter, missing the consensus estimate of -$0.71 by -$0.1.
Is Viking Therapeutics overvalued?
According to Wall Street analysts Viking Therapeutics’s price is currently Undervalued.
Does Viking Therapeutics pay dividends?
Viking Therapeutics does not currently pay dividends.
What is Viking Therapeutics’s EPS estimate?
Viking Therapeutics’s EPS estimate is -0.88.
How many shares outstanding does Viking Therapeutics have?
Viking Therapeutics has 112,444,960 shares outstanding.
What happened to Viking Therapeutics’s price movement after its last earnings report?
Viking Therapeutics reported an EPS of -$0.81 in its last earnings report, missing expectations of -$0.71. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Viking Therapeutics?
Currently, no hedge funds are holding shares in VKTX
Viking Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$90.53 (188.13% Upside)
$90.53 (188.13% Upside)
Blogger Sentiment
Bullish
VKTX Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 417.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Neutral
Last 7 Days <0.1%
Last 30 Days ▲ 0.7%
Last 30 Days ▲ 0.7%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-48.74%
12-Months-Change
Fundamentals
Return on Equity
-19.99%
Trailing 12-Months
Asset Growth
-12.57%
Trailing 12-Months
Company Description
Viking Therapeutics
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.
VKTX Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted significant progress in clinical trials for obesity treatments, with positive Phase II results and the initiation of Phase III trials. However, the financial report showed increased losses and decreased cash reserves.View all VKTX earnings summariesVKTX Stock 12 Month Forecast
Average Price Target
$90.53
▲(188.13% Upside)
Technical Analysis
Ultragenyx Pharmaceutical
―
Xenon
―
Scholar Rock Holding
―
Immunovant
―
NewAmsterdam Pharma Company
―
Ownership Overview
2.81% Insiders
22.87% Mutual Funds
0.11% Other Institutional Investors
61.38% Public Companies and Individual Investors